

#13B 3/8/02 T. Gray

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Desmond Mascarenhas
Title: NULL IGF FOR THE TREATMENT OF CANCER
Appl. No.: 09/399,120
Filing Date: 9/20/99
Examiner: F. Moezie
Art Unit: 1653

RECEIVED
FEB 25 2002
TECH CENTER 1600/2900

RESPONSE UNDER 37 C.F.R. §1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the Office Action mailed September 19, 2001, please amend the captioned application as follows:

In the Claims:

B' 1. **(Amended)** A method for slowing the growth rate of a tumor, comprising:
administering an effective amount of uncomplexed null insulin-like growth factor I (IGF-I) to a
subject having cancer.

REMARKS**Introduction**

Receipt is acknowledged of the office action dated September 19, 2001. In the action, the examiner has rejected claims 1-10 and 16 under 35 U.S.C. § 112 as allegedly indefinite and for allegedly failing to comply with the written description requirement.

By the foregoing, applicants have amended claim 1. Accordingly, claims 1-10 and 16 are pending in the present application. Support for revised claim 1 can be found on page 6, lines 24-25. Reconsideration and withdrawal of the outstanding rejections in view of the foregoing amendments and the remarks set forth below are respectfully requested.